TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Genedrive ( (GB:GDR) ).
Genedrive plc reported a significant financial turnaround with a 100% increase in revenue to £1 million and a reduced post-tax loss of £5.2 million for the year ending June 2025. The company achieved several operational milestones, including the CE-certification of its Genedrive® CYP2C19 ID Kit, facilitating its commercial progress in the EU. The product has been integrated into various NHS programs and is being used in clinical settings like Salford Royal Hospital. Genedrive also secured a positive value assessment from Scotland’s Health Technology group, leading to government investment in pharmacogenetic testing. Additionally, the Genedrive® MT-RNR1 ID Kit received a conditional recommendation from NICE and is in use across several UK hospitals, with plans for further implementation. The company is expanding its market reach internationally, with strategic partnerships and regulatory engagements in regions like the Middle East and the US.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Spark’s Take on GB:GDR Stock
According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.
Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.
To see Spark’s full report on GB:GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company specializing in the development and commercialization of rapid, low-cost, and easy-to-use point-of-care diagnostic platforms. These platforms assist clinicians in making informed decisions about medication choices and dosages, particularly in emergency healthcare settings. The company’s flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, are designed to provide quick genetic information to personalize and enhance treatment efficacy.
Average Trading Volume: 57,208,356
Technical Sentiment Signal: Sell
Current Market Cap: £10.04M
For an in-depth examination of GDR stock, go to TipRanks’ Overview page.